Purpose: To compare the histopathological changes in the human trabecular meshwork after low power argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) with a Q-switched, frequency-doubled, neod...Purpose: To compare the histopathological changes in the human trabecular meshwork after low power argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) with a Q-switched, frequency-doubled, neodymium:yttrium-alumini-um-garnet (Nd:YAG) laser. Methods: In gonioscopically normal trabecular meshwork of three patients awaiting enucleation due to malignant melanoma of the choroid SLT and ALT were per-展开更多
目的:评估选择性激光小梁成形术(SLT)在硅油乳化相关继发性开角型青光眼(SO-OAG)中的降眼压作用。方法:采用回顾性分析,选择硅油乳化取出后未达安全眼压的SO-OAG患者120例120眼,应用360° SLT治疗。评估患者治疗1wk,1、3mo后平均眼...目的:评估选择性激光小梁成形术(SLT)在硅油乳化相关继发性开角型青光眼(SO-OAG)中的降眼压作用。方法:采用回顾性分析,选择硅油乳化取出后未达安全眼压的SO-OAG患者120例120眼,应用360° SLT治疗。评估患者治疗1wk,1、3mo后平均眼压、用药种类和成功率。结果:SLT治疗1wk,1、3mo时的平均眼压分别为 17.64± 4.52、18.96±3.33、18.03±5.69mmHg,较治疗前眼压(25.02±5.93mmHg)明显降低( P =0.002、0.04、0.03);治疗1wk,1、3mo后的平均用药种类分别为1.78±0.14、1.95±0.56、1.87±0.53种,较治疗前(3.11±0.62种)明显降低( P =0.006、0.04、0.02);治疗1wk后,显效82眼(68.3%),有效24眼(20.0%);治疗1mo后,显效74眼(61.7%),有效21眼(17.5%);治疗3mo后,显效77眼(64.2%),有效15眼(12.5%)。结论:SLT能有效降低最大耐受药物治疗不能控制眼压的SO-OAG患者的眼压。展开更多
文摘Purpose: To compare the histopathological changes in the human trabecular meshwork after low power argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) with a Q-switched, frequency-doubled, neodymium:yttrium-alumini-um-garnet (Nd:YAG) laser. Methods: In gonioscopically normal trabecular meshwork of three patients awaiting enucleation due to malignant melanoma of the choroid SLT and ALT were per-
文摘目的:评估选择性激光小梁成形术(SLT)在硅油乳化相关继发性开角型青光眼(SO-OAG)中的降眼压作用。方法:采用回顾性分析,选择硅油乳化取出后未达安全眼压的SO-OAG患者120例120眼,应用360° SLT治疗。评估患者治疗1wk,1、3mo后平均眼压、用药种类和成功率。结果:SLT治疗1wk,1、3mo时的平均眼压分别为 17.64± 4.52、18.96±3.33、18.03±5.69mmHg,较治疗前眼压(25.02±5.93mmHg)明显降低( P =0.002、0.04、0.03);治疗1wk,1、3mo后的平均用药种类分别为1.78±0.14、1.95±0.56、1.87±0.53种,较治疗前(3.11±0.62种)明显降低( P =0.006、0.04、0.02);治疗1wk后,显效82眼(68.3%),有效24眼(20.0%);治疗1mo后,显效74眼(61.7%),有效21眼(17.5%);治疗3mo后,显效77眼(64.2%),有效15眼(12.5%)。结论:SLT能有效降低最大耐受药物治疗不能控制眼压的SO-OAG患者的眼压。
